<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03285503</url>
  </required_header>
  <id_info>
    <org_study_id>031-403-00049</org_study_id>
    <nct_id>NCT03285503</nct_id>
  </id_info>
  <brief_title>PK Study of Aripiprazole IM Depot for Chinese Patients With Schizophrenia</brief_title>
  <official_title>A Single-center, Uncontrolled, Open-label Clinical Trial Evaluating the Pharmacokinetic Characteristics and Safety of Aripiprazole IM Depot in Chinese Patients With Schizophrenia After Multi-dose Administration</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Otsuka Beijing Research Institute</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Otsuka Beijing Research Institute</source>
  <oversight_info>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study assess pharmacokinetics and safety of multi-administration of Aripiprazole IM
      Depot formulation at doses of 400mg in patients with schizophrenia.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      To evaluate the pharmacokinetics and safety of aripiprazole prolonged IM depot 400mg
      administered to Chinese adult subjects with schizophrenia every four weeks for 20 consecutive
      weeks
    </textblock>
  </detailed_description>
  <overall_status>Not yet recruiting</overall_status>
  <start_date type="Anticipated">May 2018</start_date>
  <completion_date type="Anticipated">April 2019</completion_date>
  <primary_completion_date type="Anticipated">February 2019</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Other</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Maximum Plasma Concentration (Cmax)</measure>
    <time_frame>up to 24 weeks</time_frame>
    <description>To assess the Maximum Plasma Concentration (Cmax) of aripiprazole and its primary metabolite OPC-14857 after administration of the fifth IMD dose.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>time of maximum observed plasma concentration (tmax)</measure>
    <time_frame>up to 24 week</time_frame>
    <description>To assess the time of maximum observed plasma concentration (tmax) of aripiprazole and its primary metabolite OPC-14857 after administration of the fifth IMD dose.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>AUC672h</measure>
    <time_frame>up to 24 weeks</time_frame>
    <description>To assess the time of maximum observed plasma concentration (tmax) of aripiprazole and its primary metabolite OPC-14857 after administration of the fifth IMD dose.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Apparent clearance after extravascular administration</measure>
    <time_frame>up to 24 weeks</time_frame>
    <description>To assess the apparent clearance after extravascular administration (CL/F) of aripiprazole after administration of the fifth IMD dose.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Adverse Events</measure>
    <time_frame>up to 24 weeks</time_frame>
    <description>Adverse events will be examined by frequency, severity, seriousness, discontinuation, and relationship to treatment</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Vital Signs</measure>
    <time_frame>up to 24 weeks</time_frame>
    <description>Mean change from baseline and the incidence of potentially clinically relevant abnormal values will be calculated for vital signs</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Laboratory Examination</measure>
    <time_frame>up to 24 weeks</time_frame>
    <description>Mean change from baseline and the incidence of potentially clinically relevant abnormal values will be calculated for routine laboratory tests (including prolactin)</description>
  </secondary_outcome>
  <other_outcome>
    <measure>Positive and Negative Symptoms Scale (PANSS)</measure>
    <time_frame>up to 24 weeks</time_frame>
    <description>To evaluate the change of Positive and Negative Symptoms Scale (PANSS) from baseline.</description>
  </other_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">12</enrollment>
  <condition>Schizophrenia</condition>
  <arm_group>
    <arm_group_label>400 mg group</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Aripiprazole IM depot 400mg will be administered every four weeks for 20 weeks after drug switch / steady dose of oral aripiprazole tablets (each subject will receive 5 intramuscular injections totally).</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Aripiprazole IM Depot</intervention_name>
    <description>administration of Aripiprazole IM Depot formulation at doses of 400 mg for 5 times in patients with schizophrenia.</description>
    <arm_group_label>400 mg group</arm_group_label>
    <other_name>ABILIFY MAINTENA</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Subjects, and their legal representatives(or their guardian ), who have signed the
             informed consent form(ICF);

          2. Patients with a diagnosis of schizophrenia as defined by DSM-IV-TR (295.30, 295.10,
             295.20,295.90 , 295.60);

          3. subjects, both male and female, who are at age between 18 and 64 (also including 18
             and 64 years of age) at time of informed consent.

        Exclusion Criteria:

          1. Presence of other mental disorders than schizophrenia confirmed through diagnostic
             criteria of DSM-IV-TR;

          2. Subjects who are alcoholomania or independent of drug, or have drug abuse history;

          3. Positive for any of HIV antibody, HBsAg, HCV antibody and syphilis serology testing;

        Other protocol-defined inclusion and exclusion criteria may apply.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>64 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Tao Jiang, Master</last_name>
    <role>Principal Investigator</role>
    <affiliation>Beijing Anding Hospital of Capital Medical University</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Wenwen Xu, Master</last_name>
    <phone>010-85182966</phone>
    <phone_ext>8035</phone_ext>
    <email>xuww@obri.otsuka.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>Beijing Anding Hospital of Capital Medical University</name>
      <address>
        <city>Beijing</city>
        <state>Beijing</state>
        <zip>100088</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Tao Jiang, Master</last_name>
      <phone>010-58303122</phone>
      <email>xinlingfangke01@126.com</email>
    </contact>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <verification_date>April 2018</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>September 11, 2017</study_first_submitted>
  <study_first_submitted_qc>September 14, 2017</study_first_submitted_qc>
  <study_first_posted type="Actual">September 18, 2017</study_first_posted>
  <last_update_submitted>April 2, 2018</last_update_submitted>
  <last_update_submitted_qc>April 2, 2018</last_update_submitted_qc>
  <last_update_posted type="Estimate">April 4, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Schizophrenia</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Aripiprazole</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>Undecided</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

